Pulmonary Embolism in Hospitalized Patient with Coronavirus Disease 2019 (COVID-19)

• Published in: Acta medica Indonesiana Vol. 53; no. 4; pp. 493 - 496
• Main Authors: Rajabto, Wulyo, Priantono, Dimas, Mulyadi, Rahmad
• Format: Journal Article
• Language: English
• Published: Indonesia 01-10-2021
• Subjects: Anticoagulants - therapeutic use; COVID-19 - complications; Humans; Pulmonary Embolism - diagnostic imaging; Pulmonary Embolism - drug therapy; Pulmonary Embolism - virology; SARS-CoV-2; Venous Thrombosis - diagnostic imaging; Venous Thrombosis - drug therapy; Venous Thrombosis - virology; COVID-19; pulmonary embolism; thrombosis
• ISSN: 0125-9326

Coronavirus disease 2019 (COVID-19) has been a global pandemic for over a year. Meanwhile, thrombosis occurs in up to one-third of hospitalized patients with the disease, while pulmonary embolism has been reported to be the most dangerous thrombosis which greatly increases mortality in COVID-19.Hospitalized patients with COVID-19 are at high risk of thromboembolic complications such as deep vein thrombosis and pulmonary embolism. The hypercoagulable state caused by COVID-19 leads to activation of coagulation cascade, meanwhile, CT pulmonary angiography is used to diagnose or exclude pulmonary embolism. Furthermore, ground-glass opacities are also evaluated using this modality. Low molecular weight heparin is the anticoagulant of choice due to simplicity in administration and low risk of drug-drug interactions.Pulmonary embolism occurs in COVID-19 patients without DVT. Based on the results, parenteral anticoagulant followed by DOAC is the mainstay of treatment in COVID-19 coagulopathy.